Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Unusually-High Trading Volume

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTAGet Free Report) saw an uptick in trading volume on Thursday . 1,186,142 shares traded hands during trading, an increase of 302% from the previous session’s volume of 294,819 shares.The stock last traded at $8.17 and had previously closed at $8.19.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CNTA. Jefferies Financial Group raised shares of Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $4.00 to $11.00 in a research report on Wednesday, November 15th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $4.00 to $8.00 in a research report on Thursday, October 26th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $9.43.

Check Out Our Latest Stock Analysis on Centessa Pharmaceuticals

Centessa Pharmaceuticals Trading Down 1.7 %

The stock’s 50 day moving average is $7.37 and its 200-day moving average is $6.94. The company has a debt-to-equity ratio of 0.29, a current ratio of 9.51 and a quick ratio of 9.51.

Centessa Pharmaceuticals (NASDAQ:CNTAGet Free Report) last posted its earnings results on Monday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.06. As a group, analysts expect that Centessa Pharmaceuticals plc will post -1.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, SVP Harris Rotman sold 4,267 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.10, for a total transaction of $34,562.70. Following the transaction, the senior vice president now owns 62,625 shares in the company, valued at approximately $507,262.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.54% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in shares of Centessa Pharmaceuticals by 0.6% in the 2nd quarter. BlackRock Inc. now owns 294,500 shares of the company’s stock worth $1,823,000 after purchasing an additional 1,840 shares during the period. Golden State Equity Partners lifted its stake in shares of Centessa Pharmaceuticals by 15.1% in the 1st quarter. Golden State Equity Partners now owns 15,970 shares of the company’s stock worth $143,000 after purchasing an additional 2,100 shares during the period. Geode Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 10.7% in the 2nd quarter. Geode Capital Management LLC now owns 25,120 shares of the company’s stock worth $155,000 after acquiring an additional 2,434 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after acquiring an additional 5,037 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Centessa Pharmaceuticals by 9.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 63,021 shares of the company’s stock worth $408,000 after acquiring an additional 5,600 shares in the last quarter. Institutional investors own 73.92% of the company’s stock.

About Centessa Pharmaceuticals

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

Further Reading

Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.